No Data
No Data
No Data
No Data
No Data
Estimating The Intrinsic Value Of Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161)
Key Insights The projected fair value for Beijing Tiantan Biological Products is CN¥25.62 based on 2 Stage Free Cash Flow to Equity With CN¥28.77 share price, Beijing Tiantan Biological Products app
Simply Wall StMay 4 06:39
Tiantan Biotech (600161): Strong profit growth in Q1 to promote the industrialization and listing of new products
Incident: Tiantan Biotech released its 2024 quarterly report. 2024Q1 achieved revenue of 1,222 million yuan, a year-on-year decrease of 5.42%, and realized net profit of 317 million yuan to mother, an increase of 20.91% over the previous year. Reviews:
信達證券May 1 00:00
Express News | Tiantan Biotech: Affiliated company obtained approval notice for drug clinical trials
BreakingsApr 29 16:47
Express News | Tiantan Biotech: Net profit for the first quarter was 317 million yuan, up 20.91% year-on-year
BreakingsApr 25 20:13
Express News | Tiantan Biology: Injectable recombinant human coagulation factor VIIII-Fc fusion protein officially launched a phase I clinical trial recently
BreakingsApr 22 16:52
Tiantan Biology (600161): The new plasma station brings about a breakthrough in the development of new products that increase the elasticity of raw plasma
Incident: The company released its 2023 annual report, achieving operating income of 5.180 billion yuan (+21.57%), net profit to mother of 1,110 billion yuan (+25.99%), and net profit not attributable to mother of 10.04 billion yuan (+29.
海通證券Apr 17 08:26
No Data
No Data